RecruitingNCT05915208
Histiocytic Disorder Follow-up Study
Sponsor
University of Alabama at Birmingham
Enrollment
6,000 participants
Start Date
Sep 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
Eligibility
Min Age: 0 YearsMax Age: 89 Years
Inclusion Criteria8
- diagnosis of histiocytic disorder at any age
- Langerhans cell histiocytosis,
- Erdheim-Chester disease,
- Rosai-Dorfman disease,
- Xanthogranuloma,
- Mixed histiocytosis
- Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
- Hemophagocytic lymphohistiocytosis
Exclusion Criteria1
- None
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05915208